Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Esposito, Antonella ^a   Floridia, Marco ^b   d'Ettorre, Gabriella ^a   Pastori, Daniele ^a   Fantauzzi, Alessandra ^a   Massetti, Paola ^a   Ceccarelli, Giancarlo ^a   Ajassa, Camilla ^a   Vullo, Vincenzo ^a   Mezzaroma, Ivano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS RNA; BENZOXAZINE DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; RETROSPECTIVE STUDY; TREATMENT RESPONSE; VIRUS LOAD; VIRUS TRANSMISSION; BLOOD; CD4 LYMPHOCYTE COUNT; COMPARATIVE STUDY; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MIDDLE AGED;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; VIRAL LOAD;

EID: 83355172217     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-341     Document Type: Article

References (29)

1. Neaton JD, Neuhaus J, Emery S. Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010. Curr Opin HIV AIDS 2010, 5:480-490.
2. Centers for Disease Control and Prevention 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS among Adolescents and Adults. JAMA 1993, 269:729-730. Centers for Disease Control and Prevention.
3. D'Arminio Monforte A, Cozzi Lepri A, Fanti I, Maggiolo F, Castagna A, Prati F, Vullo V, Quirino T, Narciso P, Lo Caputo S, Girardi E, Mussini C, Antinori A, . ICONA Foundation Study Group Proportion and trend over calendar time of patients with a low CD4 count or AIDS diagnosis at the time of their first contact with clinical care in Italy. [abstract]. 12th European AIDS Conference 2009, Cologne-Germany, ICONA Foundation Study Group.
4. Castilla J, Sobrino P, De la Fuente L, Noguer I, Guerra L, Parras F. Late diagnosis of HIV infection in the era of HAART: consequences for AIDS incidence. AIDS 2002, 16:1945-1951.
5. Sabin CA, Smith SJ, Gumley H, Murphy G, Lampe FC, Phillips AN, Prinz B, Youle M, Johnson MA. Late presenters in the era of HAART: uptake of and responses to antiretroviral therapy. AIDS 2004, 18:2145-2151.
6. Girardi E, Aloisi MS, Arici C, Pezzotti P, Serraino D, Balzano R, Vigevani G, Alberici F, Ursitti M, D'Alessandro M, d'Arminio Monforte A, Ippolito G, . the ICoNA Behavioural Epidemiology Study Group Delayed presentation and late testing for HIV: demographic and behavioral risk factors in a multi center study in Italy. J Acquir Immune Defic Syndr 2004, 36:951-959. the ICoNA Behavioural Epidemiology Study Group.
7. Sullivan AK, Curtis H, Sabin CA, Johnson MA. National review of newly diagnosed HIV infections. BMJ 2005, 330:1301-1302.
8. Castelnuovo B, Chiesa E, Rusconi S, Adorni F, Bongiovanni M, Melzi S, Cicconi P, Tordato F, Meroni L, Bini T, d'Arminio Monforte A. Declining incidence of AIDS and increasing prevalence of AIDS presenters among AIDS patients in Italy. Eur J Clin Microbiol Infect Dis 2003, 22:663-669.
9. Galvan FH, Bing EG, Bluthenthal RN. Accessing HIV testing and care. J Acquir Immune Defic Syndr 2000, 25(S2):51-56.
10. Murphy RL. Antiretroviral therapy for advanced naïve HIV-infected patients: current status and comparison of two different management strategies. J Acquir Immune Defic Syndr 2007, 46(S1):1-2.
11. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004, 18:1615-1627.
12. Jevtovic DJ, Salemovic D, Ranin J, Pesić I, Zerjav S, Djurković-Djaković O. The prevalence and risk of immune reconstitution disease in HIV-infected patients treated with HAART. HIV Med 2005, 6:140-143.
13. Connick E, Lederman MM, Kotzin BL, Spritzler J, Kuritzkes DR, St Clair M, Sevin AD, Fox L, Chiozzi MH, Leonard JM, Rousseau F, D'Arc Roe J, Martinez A, Kessler H, Landay A. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis 2000, (181):358-363.
14. French MA, Lenzo N, John M, Mallal SA, McKinnon EJ, James IR, Price P, Flexman JP, Tay-Kearney ML. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with HAART. HIV Med 2000, 1:107-115.
15. Aiuti F, Mezzaroma I. Failure to reconstitute CD4+ T cells despite suppression of HIV replication under HAART. AIDS Rev 2006, 8:88-97.
16. Bucher HC, Wolbers M, Porter K. 2010 Guidelines for Antiretroviral Treatment of HIV from the International AIDS Society-USA Panel. JAMA 2010, 304:1897.
17. EACS: Clinical Management and Treatment of HIV-infected Adults in Europe 2011. , http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/eacsguidelines-v6_english.pdf
18. Manzardo C, Zaccarelli M, Aguero F, Antinori A, Mirò JM. Optimal timing and best antiretroviral regimen in treatment-naive HIV-infected individuals with advanced disease. J Acquir Immune Defic Syndr 2007, 46(S1):9-18.
19. Zolopa A, Andersen J, Komarow L, . ACTG A5164 Study Team Immediate versus deferred ART in the setting of acute AIDS-related opportunistic infection: final results of a randomized strategy trial, ACTG A 5164. [abstract]. 15th Conference on Retroviruses and Opportunistic Infections 2008, Boston, USA, ACTG A5164 Study Team.
20. Mussini C, Manzardo C, Johnson M, Monforte A, Uberti-Foppa C, Antinori A, Gill MJ, Sighinolfi L, Borghi V, Lazzarin A, Miró JM, Sabin C, . Late Presenter Investigators Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. AIDS 2008, 22:2461-2469. Late Presenter Investigators.
21. Pulido F, Arribas JR, Miro JM, Costa MA, González J, Rubio R, Peña JM, Torralba M, Lonca M, Lorenzo A, Cepeda C, Vázquez JJ, Gatell JM, . EfaVIP Cohort Study Group Clinical, virologic and immunologic response to efavirenz or protease inhibitor- based HAART in a cohort of antiretroviral naive patients with advanced HIV infection (EFA VIP-2 Study). J Acquir Immune Defic Syndr 2004, 35:343-350. EfaVIP Cohort Study Group.
22. Riddler SA, Haubrich R, Di Rienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW, . AIDS Clinical Trials Group Study A5142 Team Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008, 358:2095-2106. AIDS Clinical Trials Group Study A5142 Team.
23. Miró JM, Manzardo C, Pich J, Domingo P, Ferrer E, Arribas JR, Ribera E, Arrizabalaga J, Loncá M, Cruceta A, de Lazzari E, Fuster M, Podzamczer D, Plana M, Gatell JM, . Advanz Study Group Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial. AIDS Res Hum Retrovir 2010, (26):747-757. Advanz Study Group.
24. Pulido F, Arribas JR, Moreno S. Similar virologic and immunologic response to efavirenz or lopinavir/ritonavir based HAART in a large cohort of antiretroviral naive patients with advanced HIV infection. [abstract]. 8th Congress on Drug Therapy in HIV Infection 2006, Glasgow, Scotland.
25. Johnson M, Sabin C, Girardi E. Definition and epidemiology of late presentation in Europe. Antivir Ther 2010, 15(S1):3-8.
26. Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, Moyle G, Mancini M, Percival L, Yang R, Thiry A, McGrath D, . CASTLE Study Team Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008, 372:646-655. CASTLE Study Team.
27. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, Zhao J, Xu X, Williams-Diaz A, Rodgers AJ, Barnard RJ, Miller MD, DiNubile MJ, Nguyen BY, Leavitt R, Sklar P, . STARTMRK investigators Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009, 374:796-806. STARTMRK investigators.
28. Soria A, Lazzarin A. Antiretroviral treatment strategies and immune reconstitution in treatment naïve HIV-infected patients with advanced disease. J Acquir Immune Defic Syndr 2007, 46(Suppl):19-30.
29. Cooper DA, Heera J, Goodrich J, Tawadrous M, Saag M, Dejesus E, Clumeck N, Walmsley S, Ting N, Coakley E, Reeves JD, Reyes-Teran G, Westby M, Van Der Ryst E, Ive P, Mohapi L, Mingrone H, Horban A, Hackman F, Sullivan J, Mayer H. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010, 201:803-813.